| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total operating expenses | 87,542 | 91,093 | 91,069 | 58,651 |
| Loss from operations | -31,284 | -38,503 | -41,028 | -11,000 |
| Other income, net | 2,894 | 3,616 | 3,660 | 4,756 |
| Loss before income taxes | -28,390 | -34,887 | -37,368 | -6,244 |
| Benefit for income taxes | -5,804 | -7,680 | -7,874 | -920 |
| Net loss | -22,586 | -27,207 | -29,494 | -5,324 |
| Basic (in dollars per share) | -0.38 | -0.46 | -0.5 | -0.09 |
| Basic (in shares) | 59,091,478 | 58,993,990 | 58,527,775 | 58,261,961 |
| Diluted (in dollars per share) | -0.38 | -0.46 | -0.5 | -0.09 |
| Diluted (in shares) | 59,091,478 | 58,993,990 | 58,527,775 | 58,261,961 |
Vanda Pharmaceuticals Inc. (VNDA)
Vanda Pharmaceuticals Inc. (VNDA)